Roche’s Genentech says VOYAGER real-world study supports Vabysmo effectiveness across wet AMD, DME, RVO

• Roche unit Genentech released new real-world VOYAGER study data on Vabysmo across wet AMD, DME, RVO.
• Results will be presented at the EURETINA 2026 Annual Meeting in Vienna.
• Study showed vision outcomes improved in previously untreated patients, remained broadly stable in previously treated patients.
• Imaging outcomes improved across groups, supporting durability in routine practice with fewer injections later in the first year.
• Safety profile matched prior Phase III studies, reinforcing Vabysmo’s positioning across major retinal indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930817201) on October 01, 2026, and is solely responsible for the information contained therein.